Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.

Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, Li J, Chen Q.

Eur J Cancer. 2010 Oct;46(15):2781-7. doi: 10.1016/j.ejca.2010.05.022. Epub 2010 Jun 25. Review.

PMID:
20580219
2.

A comparability study of 5 commercial KRAS tests.

Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, Gyuris T, Baron W, Bakker A, Parker A, Patterson SD.

Diagn Pathol. 2010 Apr 16;5:23. doi: 10.1186/1746-1596-5-23.

3.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
4.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

5.

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS.

Oncology. 2009;77(3-4):224-30. doi: 10.1159/000236046. Epub 2009 Sep 7.

PMID:
19738388
6.

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F.

Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. doi: 10.1038/nrclinonc.2009.111. Epub 2009 Jul 28. Review.

PMID:
19636327
7.

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA.

Br J Cancer. 2009 Aug 4;101(3):465-72. doi: 10.1038/sj.bjc.6605164. Epub 2009 Jul 14.

8.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.

9.

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.

J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.

10.

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.

Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T.

Br J Cancer. 2009 Apr 21;100(8):1330-5. doi: 10.1038/sj.bjc.6605008.

11.

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S.

Clin Cancer Res. 2009 May 1;15(9):3184-8. doi: 10.1158/1078-0432.CCR-08-2961. Epub 2009 Apr 14.

12.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

13.

KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2009 Jan;23(6):1-3. No abstract available.

PMID:
19297803
14.

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.

Molinari F, Martin V, Saletti P, De Dosso S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L, Frattini M.

Br J Cancer. 2009 Apr 7;100(7):1087-94. doi: 10.1038/sj.bjc.6604848. Epub 2009 Mar 17.

15.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.

16.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

17.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
18.

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, Jakobsen A.

Ann Oncol. 2009 May;20(5):879-84. doi: 10.1093/annonc/mdn712. Epub 2009 Jan 29.

19.

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.

J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.

20.

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG.

J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29.

Items per page

Supplemental Content

Write to the Help Desk